1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Baseline characteristicsa
Characteristics
Patient background
 Age (yr)74.9 [SD, 13.1]
 Atrial fibrillation16 (72.7%)
 Hypertension13 (59.1%)
 Diabetes mellitus2 (9.1%)
 Dyslipidemia12 (54.5%)
 Chronic kidney disease11 (50%)
Clinical status and treatment
 NIHSS at arrival13.9 [SD, 5.9]
 Sedation (midazolam)6 (27.3%)
 IV rtPA therapy8 (40.9%)
 TICI Grade 2a1 (4.5%)
  Grade 2b5 (22.7%)
  Grade 316 (72.7%)
 Puncture-to-recanalization time (min)66.2 [SD, 25.2]
 Total contrast dose (mL)130.3 [SD, 39.4]
 mRS pre-onset0.6 [SD, 1.2]
   90-day post-MT2.7 [SD, 1.9]
  • ↵a Data are presented as mean [SD] or No. (%).